文献速递肿瘤 PET/CT

靶向PD-1和CTLA-4的免疫检查点抑制剂治疗的转移性黏膜与皮肤黑色素瘤的预后18F-FDG PET生物标志物

Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-03-23

本回顾性单中心研究纳入56例不可切除黏膜黑色素瘤(24例)或皮肤黑色素瘤(32例)患者,于2011至2017年间在免疫检查点抑制剂治疗前接受基线18F-FDG-PET/CT,比较影像生物标志物的预后价值。黏膜黑色素瘤中仅高基线SUVmax与较短总生存相关,皮肤黑色素瘤中高TMTV和高BLR与较短总生存、较短无进展生存及较低缓解独立相关。

要点

  • 黏膜黑色素瘤中,升高的肿瘤SUVmax与较短总生存相关,与PFS、ORR、DCR无相关。
  • 皮肤黑色素瘤中,升高的TMTV和升高的BLR与较短OS、较短PFS及较低缓解独立相关。
  • 全部黏膜和皮肤黑色素瘤病灶均为FDG高摄取,但预后影像生物标志物不同。

核心结论

  • 全部黏膜黑色素瘤和皮肤黑色素瘤均为FDG高摄取,但两类患者的预后影像生物标志物不同。
  • 黏膜黑色素瘤患者中唯一的预后影像生物标志物是高基线最大糖酵解活性(SUVmax)。
  • 皮肤黑色素瘤患者中基线代谢肿瘤负荷或骨髓代谢与免疫检查点抑制剂缓解持续时间呈负相关。

研究设计与样本

  • 回顾性单中心研究,纳入56例不可切除黏膜黑色素瘤(n=24)或皮肤黑色素瘤(n=32)患者。
  • 患者于2011至2017年间在免疫检查点抑制剂治疗前接受基线18F-FDG-PET/CT。
  • 从肿瘤组织提取SUVmax、SUVmean、TMTV和TLG,从淋巴组织提取BLR和SLR。
  • 采用Cox预测模型、Student t检验和Spearman相关分别评估与生存和缓解的关联,p<0.05为显著。

主要发现

  • 免疫检查点抑制剂以抗PD-1为主(92.9%,n=52/56),全部18F-FDG-PET/CT均为阳性。
  • 总体(黏膜黑色素瘤比皮肤黑色素瘤)ORR为33%比42%,DCR为56%比69%。
  • 总体中位随访为25.0比28.9个月,中位PFS为4.7比10.7个月,中位OS为23.9比28.3个月。
  • 黏膜黑色素瘤中升高的肿瘤SUVmax与较短OS相关,与PFS、ORR、DCR无相关。
  • 皮肤黑色素瘤中升高的TMTV和升高的BLR与较短OS、较短PFS及较低缓解(ORR、DCR)独立相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the prognostic value of imaging biomarkers derived from a quantitative analysis of baseline 18F-FDG-PET/CT in patients with mucosal melanoma (Muc-M) or cutaneous melanoma (Cut-M) treated with immune checkpoint inhibitors (ICIs). METHODS: In this retrospective monocentric study, we included 56 patients with non-resectable Muc-M (n = 24) or Cut-M (n = 32) who underwent baseline 18F-FDG-PET/CT before treatment with ICIs between 2011 and 2017. Parameters were extracted from (i) tumoral tissues: SUVmax, SUVmean, TMTV (total metabolic tumor volume), and TLG (total lesion glycolysis) and (ii) lymphoid tissues: BLR (bone marrow-to-liver SUVmax ratio) and SLR (spleen-to-liver SUVmax ratio). Association with survival and response was evaluated using Cox prediction models, Student's t tests, and Spearman's correlation respectively. p < 0.05 was considered significant. RESULTS: Majority of ICIs were anti-PD1 (92.9%, n = 52/56). All 18F-FDG-PET/CT were positive. Overall (Muc-M to Cut-M), ORR was 33%:42%, DCR was 56%:69%, median follow-up was 25.0:28.9 months, median PFS was 4.7:10.7 months, and median OS was 23.9:28.3 months. In Muc-M, increased tumor SUVmax was associated with shorter OS while it was not correlated with PFS, ORR, or DCR. In Cut-M, increased TMTV and increased BLR were independently associated with shorter OS, shorter PFS, and lower response (ORR, DCR). CONCLUSION: While all Muc-M and Cut-M were FDG avid, prognostic imaging biomarkers differed. For Muc-M patients treated with ICI, the only prognostic imaging biomarker was a high baseline maximal glycolytic activity (SUVmax), whereas for Cut-M patients, baseline metabolic tumor burden or bone marrow metabolism was negatively correlated to ICI response duration.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Seban RD, Moya-Plana A, Antonios L, et al. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. Eur J Nucl Med Mol Imaging. 2020. PMID: 32206839. doi:10.1007/s00259-020-04757-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。